Join us on December 14 for our Patient-Focused Sessions on Multiple Myeloma, taking place in Charlotte, NC! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Kristie L. Kahl
The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.
Jessica Skarzynski
While radiation therapy may be a common alternative for inoperable hepatocellular carcinoma, two new studies suggest that proton radiation therapy may offer the same benefits as the more traditionally used photon radiation therapy, with less toxicity.
Beth Fand Incollingo
Nearly one-quarter of inoperable intrahepatic cholangiocarcinomas shrank enough to make surgery possible after selective internal radiation was added to chemotherapy, a study shows.
Katie Kosko
Both men and women have seen an increase in liver cancer diagnoses and death over the past nearly 20 years, according to new study findings.
Jessica Skarzynski
For Liver Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
Kristie L. Kahl
Frontline treatment with Opdivo improved overall survival and response rates among patients with advanced hepatocellular carcinoma, however, the trial missed its primary endpoint.
Sonya Collins
As immunotherapies emerge in the treatment of liver cancer, experts examine whether two or more is better than one.
Jessica Skarzynski
Taking aspirin was found to improve liver function and extend survival among patients with hepatocellular carcinoma – the most common primary liver cancer.
Kristie L. Kahl
Researchers at Roswell Park Comprehensive Cancer Center found a biomarker that may help to determine which patients with hepatocellular carcinoma will respond to treatment with Nexavar, leading to more individualized treatment options.
Katie Kosko
A team of researchers examine funding among different cancer types, exposing disparities in cervical, colon, endometrial, liver and bile duct, lung, ovarian and pancreatic cancer.

Sign In

Not a member? Sign up now!
Continue without login